title: Longitudinal epidemiology of multidrug-resistant (MDR) Acinetobacter species in a tertiary care hospital.
abstract: BACKGROUND
  Acinetobacter species are well-known causes of health care-associated infections. The longitudinal epidemiology of this species in the hospital setting is poorly understood. A sudden, persistent increase in multidrug-resistant (MDR) A baumannii infections occurred beginning in June 2006 at Temple University Hospital in Philadelphia. An analysis was done to describe the longitudinal molecular epidemiology of MDR A baumannii in a tertiary care hospital.
  
  
  METHODS
  This was an epidemiologic investigation using repetitive extragenic palindromic-PCR (rep-PCR) of patients with a positive culture for MDR A baumannii admitted to the hospital between February 2006 and January 2010. MDR A baumannii were defined as susceptible only to colistin and/or tigecycline.
  
  
  RESULTS
  The incidence rate of MDR A baumannii rose from 0.36 cases per 1,000 patient-days (pre-epidemic) to 0.86 cases per 1,000 patient-days, due mainly to an increase in the surgical intensive care unit. Enhanced infection control measures were implemented, but waves of MDR A baumannii continued to be documented through routine surveillance. Of 32 strains collected in 2006-2007, a single predominant clone and 2 minor clones accounted for almost all of the cases of MDR A baumannii studied. Of 24 strains collected in 2008-2009, another clone, different from those studied in the earlier period, predominated, and was accompanied by 3 minor variants.
  
  
  CONCLUSIONS
  Following an outbreak in the surgical intensive care unit, MDR A baumannii persisted in our institution for a 3-year period despite rigorous infection control measures. An unexpected strain replacement occurred during this period, with the original predominant strain disappearing completely and new minor clones displacing the original minor clones.
authors.affiliation: Section of Infectious Diseases, Temple University School of Medicine, Philadelphia, PA, USA.
authors.forename: Ji Hoon
authors.initials: JH
authors.lastname: Baang
authors.forename: Peter
authors.initials: P
authors.lastname: Axelrod
authors.forename: Brooke K
authors.initials: BK
authors.lastname: Decker
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Hujer
authors.forename: Georgia
authors.initials: G
authors.lastname: Dash
authors.forename: Allan R
authors.initials: AR
authors.lastname: Truant
authors.forename: Robert A
authors.initials: RA
authors.lastname: Bonomo
authors.forename: Thomas
authors.initials: T
authors.lastname: Fekete
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects / Q000235:genetics*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015373:Bacterial Typing Techniques; D003091:Colistin / Q000008:administration & dosage / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D004196:Disease Outbreaks; D024901:Drug Resistance, Multiple, Bacterial; D006761:Hospitals; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units; D008137:Longitudinal Studies; D008911:Minocycline / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015143:Philadelphia / Q000453:epidemiology; D016133:Polymerase Chain Reaction; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline; D003091:Colistin